Compound libraries
Products
EBC main page
Search
Dyes
Impurities
Chemical probes
Contacts us
Pfizer reference compounds
Services
© 2026 Copyright Enamine
Back
Product details:
CAS
1454846-35-5
Purity
95%
Lorlatinib is a third-generation ALK tyrosine kinase receptor inhibitor. It is indicated for the treatment of adult patients with ALK-positive metastatic non-small cell lung cancer.
Properties
Name
Lorlatinib
Smiles
C[C@H]1OC=2C=C(C=NC2N)C3=C(C#N)N(C)N=C3CN(C)C(=O)C=4C=CC(F)=CC14
Targets
Please log in to see this information
Sold for research purposes under agreement from Pfizer Inc.
SDS
PF-06463922 | loratinib | lorlatinib
No data available
The compound has purity validated by NMR and/or LCMS methods.
1 mg
$37
2 mg
$39
5 mg
$41
10 mg
$43
15 mg
$45
20 mg
$48
25 mg
$53
30 mg
$55
35 mg
$58
40 mg
$60
45 mg
$63
50 mg
$65
75 mg
$68
100 mg
$POA
Quantity
1
Total amount
$ 41
PF-06463922 | loratinib | lorlatinib
No data available
The compound has purity validated by NMR and/or LCMS methods.
Target activity features
It should be emphasized that the product may be active against a larger number of targets than shown on the card. The information represented here refers to the targets with the largest value of pX or the targets with ΔpX less than 1.5 from the largest pX value.
CAS:1924207-18-0
0